Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Novel Approaches Emerge in AL Amyloidosis
Much like multiple myeloma, the treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies, says Michael Rosenzweig, MD.
Daratumumab (Darzalex) has been shown to induce deep and rapid hematologic responses in pretreated patients with AL amyloidosis. Results from a prospective phase II study showed that the hematologic complete response rate was 17% in 24 evaluable patients. Additionally, 29% of patients experienced a very good partial response, and 17% achieved a partial response. The overall response rate for daratumumab in this population was 63%.
Early data for the novel anti-amyloid fibril therapy, 11-1F4, also known as CAEL-101, have suggested preliminary signals of efficacy as well, said Rosenzweig.
myBinderRelated Content
-
Imaging AL Light Chain Amyloidosishttps://www.youtube.com/watch?v=bSxomM5r...
-
ISA 2020 | AL Amyloidosis: Multidisciplinary Treatment Approachhttps://www.youtube.com/watch?time_conti...
-
Center for Advanced Heart and Lung Disease – Baylor University Medical CenterThe Center for Advanced Heart and Lung...
-
Surbhi Sidana, MDDr. Surbhi Sidana is an Assistant profes...
-
Steroids for AL AmyloidosisSteroids are drugs which mimic certain h...
-
Gregory Foster AL Amyloidosis “A Fight for Answers”https://www.youtube.com/watch?v=HkKTyKBr...
-
Van Selby, MDDr. Van Selby is a cardiologist who spec...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
